Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kyoto Institute of Advanced Technology (KIAT) is a Japanese biotechnology company specializing in the production of recombinant proteins using a proprietary silkworm-based expression system. The company utilizes silkworms as bio-reactors to express complex proteins that are often difficult to produce in traditional microbial or mammalian cell cultures. KIAT's platform leverages the silkworm-baculovirus expression system to provide high-yield and cost-effective protein production services. Their offerings include contract research services for protein expression, purification, and the development of diagnostic reagents. The company supports a wide range of applications in drug discovery, structural biology, and clinical diagnostics for global pharmaceutical and academic partners. Based in the Kyoto University Katsura Venture Plaza, KIAT remains a niche leader in insect-based biomanufacturing technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kyoto Institute of Advanced Technology.